Ipratropium formulation for pulmonary inhalation
April 23, 2021. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References 3505337 Methods for the treatment of nasal hypersecretion Aerosol drug formulations Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content Medicinal aerosol formulations Aerosol valve with a surfactant impregnated valve seal Aerosol composition of a salt of ipratropium and a salt of albuterol Canister containing aerosol formulations containing P134a and particulate medicaments Pharmaceutical formulation Method of intrapulmonary administration of a narcotic drug InventorsAssigneeApplicationNo. 841181 filed on 04/23/2001US Classes:424/45, Organic pressurized fluid424/46, Powder or dust containing424/434, Mucosal (e.g., nasal, etc.)424/435, Mouth424/489Particulate form (e.g., powders, granules, beads, microcapsules, and pellets)ExaminersPrimary: Dees, Jose G.Assistant: Haghighatian, Mina Attorney, Agent or FirmForeign Patent References
International ClassesA61K 009/12A61K 009/14 AbstractPharmaceutical aerosol formulations are provided comprising substantially nonacicular particles of a bronchodilator selected from the group consisting of ipratropium and pharmacologically acceptable salts, solvates, hydrates, esters and isomers thereof. The described formulations include a propellant selected from the group consisting of a fluorocarbon propellant, a hydrogen-containing fluorocarbon propellant, and mixtures thereof. The formulations are substantially free of both surfactant and solvent. Methods of use and drug delivery devices are also provided.Other References
| |
